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Background: Gemcitabine (2′, 2′ –difluorodeoxycytidine) is one of many nonplatinum drugs that exhibit activity in
recurrent, platinum-resistant ovarian cancer. However, the molecular mechanisms by which Gemcitabine treatment
inhibits the proliferation of platinum-resistant ovarian cancer cells still remain unclear. We investigated whether
Gemcitabine increases the efficacy of Cisplatin in platinum-resistant ovarian cancer models in vitro and in vivo.
Methods: We used Cisplatin-resistant Caov-3 cells, A2780CP cells and Cisplatin-sensitive A2780 cells to examine the
sensitivity of the cell viability of Cisplatin and Gemcitabine using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and the sensitivity of the invasive activity of Cisplatin and
Gemcitabine using an invasion assay with Matrigel. We examined the Akt kinase activity and matrix
metalloproteinase 9 (MMP9) expression following Cisplatin and Gemcitabine treatment using a Western blot analysis
and the mRNA expression of vascular endothelial growth factor (VEGF) using semi-quantitative RT-PCR. Moreover,
we evaluated the effects of Cisplatin and Gemcitabine on the intra-abdominal dissemination of ovarian cancer
in vivo.
Results: Gemcitabine significantly inhibited Cisplatin-induced Akt activation in the Caov-3 and A2780CP cells, but
not in the A2780 cells. In the presence of Gemcitabine, Cisplatin-induced growth inhibition and apoptosis were
significantly enhanced in the Caov-3 and A2780CP cells. Co-treatment with Cisplatin and Gemcitabine almost
completely inhibited invasion of both types of cells through the Matrigel; however, neither Cisplatin nor
Gemcitabine alone inhibited the invasion of both types of cells. Gemcitabine inhibited not only the
Cisplatin-induced activation of Akt, but also the MMP9 and mRNA expression of VEGF. Moreover, treatment with
Gemcitabine increased the efficacy of Cisplatin-induced growth inhibition of the intra-abdominal dissemination and
production of ascites in the athymic nude mice inoculated with Caov-3 cells.
Conclusions: We herein demonstrated that Gemcitabine inhibits the Akt kinase activity and angiogenetic activity
following treatment with Cisplatin in platinum-resistant ovarian cancer cells. These results provide a rationale for
using Gemcitabine in clinical regimens containing molecular targeting agents against platinum-resistant ovarian
cancers.
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Ovarian cancer is a major cause of death among patients
with gynecological malignancies. There was some im-
provement in the survival time following the introduction
of platinum (Cisplatin or Carboplatin) and Paclitaxel ther-
apy; however, the likelihood of success in the treatment of
females with advanced, recurrent or persistent ovarian
cancer has remained largely unchanged for four decades
[1]. Therefore, there is a need to consider the use of
second-line chemotherapeutic options in ovarian cancer
patients [2-8]. However, the patient response rates to
second-line therapy are strikingly different depending on
the platinum sensitivity of the cancer. Furthermore, clear
cell carcinoma and mucinous adenocarcinoma in ad-
vanced stages (III and IV) have been reported to be associ-
ated with a lower survival rate due to resistance to
platinum-based chemotherapy [9-11]. Accordingly, the
important determinant of the patient prognosis thus
seems to be whether the ovarian cancer is sensitive or re-
sistant to platinum.
The balance between cellular survival and apoptosis
determines the sensitivity of cells to chemotherapeutic
drug-induced apoptosis. Therefore, it is possible that
antiapoptotic signals, such as the phosphatidylinositol 3-
kinase (PI3K)-Akt survival cascade, plays a role in tumor
sensitivity to chemotherapeutic drugs. We previously re-
ported that Akt inactivation sensitizes human ovarian
cancer cells to Cisplatin [12,13] and Paclitaxel [14].
Hence, the inhibition of antiapoptotic signals, such as
those mediated by the Akt pathway, has been proposed
to be a promising strategy for enhancing the efficacy of
conventional chemotherapeutic agents [15]. Since the
PI3/Akt cascade is involved in Cisplatin resistance, inhi-
biting this cascade using gene transfection is effective in
reversing Cisplatin resistance [12,16]. However, small
molecular agents that block the Akt cascade have not so
far been available in the clinical setting.
Gemcitabine (2′, 2′ –difluorodeoxycytidine) is one of
many non-platinum drugs that exhibit activity in recur-
rent, platinum-resistant ovarian cancer [17]. Interestingly,
preclinical studies have suggested that Gemcitabine may
have an additive or synergistic effect when combined with
Cisplatin [18]; clinical studies of groups of females who
have previously received multiple lines of therapy support
this notion [19,20]. Moreover, it has been reported that
Gemcitabine induces apoptosis in human pancreatic can-
cer cells, in part, by downregulating the PI3K-Akt signal-
ing pathway [21].
These considerations led us to examine whether Gem-
citabine inhibits the PI3K/Akt signaling pathway in ovar-
ian cancer cells. In the present study, we found that
Gemcitabine attenuates the PI3K/Akt cascade and in-
creases the efficacy of Cisplatin in Cisplatin-resistant
ovarian cancer cell lines both in vitro and in vivo.Materials and methods
Reagents/antibodies
Gemcitabine hydrochloride was purchased from LKT
Laboratories, Inc. (Minnesota, USA) and dissolved in
sterile water. Cisplatin was purchased from Sigma-Aldrich
(Dorset, UK). Antiphospho-Akt (ser473), anti-Akt, anti-
PARP, anti-MMP9 antibodies were purchased from Cell
Signaling Technology (Beverly, MA).
Cell lines
The human ovarian cisplatin-resistant Caov-3 cells,
cisplatin-resistant A2780CP cells and cisplatin-sensitive
A2780 cells were obtained from the American Type
Culture Collection (Rockville, MD). The cells were cul-
tured at 37°C/5% CO2 in DMEM supplemented with
10% FBS in a humidified atmosphere. All mice were
purchased from Japan SLC (Shizuoka, Japan).
Proliferation assay
Cell proliferation was assessed using an 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium (MTS) assay. We examined the
effects of Cisplatin or Gemcitabine alone and in combin-
ation on the proliferation of the Caov-3, A2780CP and
A2780 cells using a proliferation assay.
A total of 5 × 105 cells cultured at 37°C in a humidi-
fied, 5% CO2 atmosphere in serum-free DMEM for
24 hours and pretreated with PBS or Cisplatin at various
concentrations or 100 nM of Gemcitabine for 12 hours
followed by PBS or Cisplatin at various concentrations
were seeded into each well. The assays were performed
after 24 hours by adding 20 μl/well of the CellTiter 96®
AQueous One Solution Reagent (Promega Corporation,
USA) directly to the culture wells, incubating for one to
two hours and then recording the absorbance at 490 nm
with a 96-well plate reader. All experiments were carried
out in quadruplicate, and the viability was expressed as
the ratio of the number of viable cells treated with Cis-
platin to the number of viable cells treated without Cis-
platin. Each point represents the mean ± SD of four
experiments. We examined whether the co-treatment
with cisplatin and gemcitabine leads to synergistic inhib-
ition of cell viability in the Caov-3, A2780CP and A2780
cells, and calculated synergistic effects using a Mixlow
method of Assessing Drug Synergism/Antagonism [22].
The MixLow program was coded in the R (R Foundation
for Statistical Computing, Austria).
Cell invasion assay
The invasive potential was assessed using the Invasion
assay. We examined the effects of Cisplatin or Gemcita-
bine alone and in combination on the invasive potential
of the Caov-3, A2780CP and A2780 cells using an inva-
sion assay. A total of 5 × 105 cells cultured at 37°C in a
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for 24 hours and pretreated with PBS or 100 μM of Cis-
platin or 100 nM of Gemcitabine for 12 hours followed
by PBS or 100 μM of Cisplatin were seeded into the
upper wells coated with a thin layer of Matrigel. The
lower chamber was coated with 600 μL of DMEM. Fol-
lowing 24 hours of incubation at 37°C, the non-invading
cells on the surface of the Matrigel-coated membrane
were removed by scraping with a cotton swab. Cells that
had migrated through the Matrigel were stained with
hematoxylin. Following several washes with PBS, the
stained cells were manually counted for three independ-
ent experiments. Each point represents the mean ± SD
of four experiments.Western blot analysis
The cells were starved and treated with PBS or 100 μM
of Cisplatin for 24 hours with or without being pre-
treated with 100 nM of Gemcitabine for 12 hours. The
cells were then washed twice with ice-cold phosphate-
buffered saline, lysed and separated to cytoplasmic and
nuclear fractions using the Nuclear Extract Kit according
to the manufacturer’s protocol (Active Motif, Carlsbad,
CA). To detect Akt, phosphorylated Akt, MMP9 and
PARP proteins, we separated the proteins using SDS
polyacrylamide gel electrophoresis and electrotransferred
them to nitrocellulose membranes. Western blot ana-
lyses were performed using various specific primary anti-
bodies. The immunoreactive bands in the immunoblots
were visualized with horseradish peroxidase-coupled
goat anti-rabbit immunoglobulin using an enhanced
chemiluminescence Western blotting system (ECL Plus,
GE Healthcare Life Sciences, Pittsburgh, PA, USA).
Nonspecific antigen sites were blocked with 10% bovine
serum albumin in 1× Tris-buffered saline.Gelatin zymography
MMP-9 activity was measured with a gelatin-
zymography kit (Primary Cell, Sapporo, Japan) according
to the manufacturer’s instructions. Caov-3 cells were
seeded in 6-well plates at 5 × 105 cells/mL. Cells were
cultured in serum-free DMEM for 24 hours and treated
with PBS or 100 μM of Cisplatin or 100 nM of Gemcita-
bine or in combination for 12 hours at 37°C in a humidi-
fied, 5% CO2 atmosphere.
Thereafter, the cultured supernatants were collected
and electrophoresed in gelatin at 15 mA constant for
90 minutes. After renaturing and developing the Gel,
adding 40 mL of SimplyBlue Safestain and incubate for
1 hour at room temperature under gentle agitation.
After staining, gels were scanned with a resolution of
300 dpi. And the respective band densitometry analyses
were performed using the Image J software program.RNA extraction and semi-quantitative reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was obtained using the RNeasy Mini kit
(Qiagen, Germantown, MD, USA) from cells starved for
24 hours then treated with PBS or 100 μM of Cisplatin
for 24 hours with or without being pretreated with 100
nM of Gemcitabine for 12 hours. A total of 2 μg of total
RNA was reverse-transcribed with Superscript II RNase
H-reverse transcriptase (Invitrogen, Carlsbad, CA,
USA) using random primers according to the manufac-
turer’s instructions. The cDNA (1 μl) was amplified
using 0.1 μM of each primer, 1 U of Taq DNA polymer-
ase (Roche Diagnostics, Mannheim, Germany), PCR
buffer with 1.5 mM of MgCl2 and 0.25 mM of dNTPs in
a 20-μl reaction volume using a PTC200 Thermal cycler
(Bio-Rad Laboratories, Hercules, CA, USA). The ampli-
fication conditions were as follows: initial denaturation
at 94°C for three minutes, followed by 28 cycles com-
prising denaturation at 94°C for 30 seconds, annealing
at the optimized temperature for each set of primers for
30 seconds and extension at 72°C for 30 seconds. The
final extension was carried out for five minutes at 72°C.
The products were analyzed on 2.0% (w/v) agarose gels
stained with 0.5 mg/ml ethidium bromide (Sigma-Aldrich)
and visualized under an ultraviolet transilluminator. The
product size was approximated using a 100-bp DNA
ladder (Bangalore Genei, Bangalore, India). The negative
control did not contain reverse transcriptase (RT) en-
zymes in the reaction mixture. The PCR primers for the
Taqman/Probe Library assays were designed using the
Probe Library Assay Design Center (Roche) as follows:
VEGF-F:5′-AGGAGGAGGGCAGAATCATCA -3′, and
reverse, VEGF-R: 5′-CTCGATTGGATGGCAGTAGCT -3′.
Quantitative RT-PCR was performed on a LightCycler
2.0 (Roche Diagnostics, Indianapolis, IN), and the results
were analyzed with the LightCycler Software program
4.05 (Roche Diagnostics) using a calibrator-normalized
relative quantification approach. The relative gene ex-
pression quantification was normalized to the β-actin
expression.
In vivo growth inhibition assay
Female 6-week-old athymic nude mice (BALB/c Slc-nu/
nu) were used for the tumor experiments. The mice had
access to sterile food pellets and water ad libitum. The
institutional guidelines for animal welfare and experi-
mental conduct were followed. Caov-3 cells were sus-
pended in PBS, after which 5 × 106 cells were injected i.
p. into each of the 20 female 6-week-old nude mice.
Two weeks after the inoculation of Caov-3 cells, the
athymic nude mice were randomly assigned to one of
four groups treated with the following regimens for six
weeks: (a) vehicle (PBS); (b) Cisplatin (5 mg/kg) once a
week; (c) Gemcitabine (60 mg/kg) once a week; and (d)
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kg) once a week. The abdominal circumference was mea-
sured weekly. Eight weeks after the initiation of treatment,
all mice were sacrificed.
Apoptosis detection and immunohistochemistry
At sacrifice, the liver, bowels and uterus were excised,
flushed with PBS and fixed in formalin overnight. Five-
micron sections obtained from the liver, bowels and
uterus of the mice were fixed in formalin and embedded
in paraffin then prepared for the immunohistochemical
analyses. The degree of apoptosis was analyzed with the
ApopTag® Plus Peroxidase In Situ Apoptosis Kit (EMD
Millipore Headquarters, USA), while the proliferation
index was evaluated by staining for Ki67 and the micro-
vessel density was evaluated by staining for CD31 anti-
gens. The percentage of apoptotic cells and the MIB-1
index reflected the percentage of the total number of
tumor cells with nuclear staining. In addition, the per-
centage of the vessel area was calculated as the ratio of
the number of CD31-positive vessels in the tumor as an
index of angiogenesis. All parameters were obtained in
three different mice, and all values represent the mean ±
SD of the results of three mice in each group.
Statistics
The data represent the mean ± SD of three to five inde-
pendent experiments. The statistical analysis was per-
formed using Student’s t-test at a significance level of P <
0.05 to < 0.01. The symbol (*) indicates p < 0.05 and the
symbol (**) indicates P < 0.01 compared with the control.
Results
Gemcitabine specifically enhances the Cisplatin-induced
inhibition of cell viability
The sensitivity cell viability of Cisplatin in the Caov-3,
A2780CP and A2780 cells was examined using an MTS
assay. It was first confirmed that A2780 cells are sensitive
and Caov-3 and A2780CP cells are resistant to Cisplatin,
as previously reported [16]. As shown in Figure 1A,B andFigure 1 Gemcitabine enhances the Cisplatin-induced inhibition of ce
(B) and A2780 (C) cells was examined using an MTS assay. The cells were t
100 nM of Gemcitabine (GEM). Twenty-four hours later, the cell viability wa
Methods”. Significant differences are indicated by asterisks. **, p < 0.01.C, the viability of the Caov-3 and A2780CP cells, but not
the A2780 cells, remained unaffected by increasing the
concentration of Cisplatin to over 200 μM or that of Gem-
citabine to over 1,000 nM. We examined whether the
co-treatment with cisplatin and gemcitabine leads to syn-
ergistic inhibition of cell viability in the Caov-3 and
A2780CP cells using a Mixlow method of Assessing Drug
Synergism/Antagonism [22]. There was synergistic inhib-
ition of cell viability in the Caov-3 (combination index
(CI) = 0.74845) and A2780CP cells (CI = 0.49595) follow-
ing the combined treatment with Cisplatin and Gemcita-
bine (Figure 1A and 1B, Additional file 1: Figure S1).
Gemcitabine specifically enhances the Cisplatin-induced
inhibition of cell invasion through Matrigel
The sensitivity of the invasive activity of Cisplatin in the
Caov-3, A2780CP and A2780 cells was examined using
an assay of the invasion through Matrigel. We examined
the effects of Cisplatin and Gemcitabine alone and in
combination on the invasion of the Caov-3, A2780CP
and A2780 cells through the Matrigel. Although neither
Cisplatin nor Gemcitabine inhibited the invasion of the
Caov-3 or A2780CP cells through the Matrigel, co-
treatment with Cisplatin and Gemcitabine almost com-
pletely inhibited the invasion of both of these cell lines
through the Matrigel (Figure 2A and 2B). In contrast,
both Cisplatin and Gemcitabine almost completely
inhibited the invasion of the A2780 cells through the
Matrigel (Figure 2C).
Cisplatin activates the Akt survival pathway in
Cisplatin- resistant cell lines
We examined the Akt kinase activity following treat-
ment with Cisplatin or Gemcitabine individually and in
combination. We observed that Cisplatin induced Akt
phosphorylation in both the Caov-3 and A2780CP cells,
although there was no synergistic effect in the A2780
cells (Figure 3A, 3B and 3C). Gemcitabine had no effect
on the levels of Akt phosphorylation. However, the
combination of Cisplatin and Gemcitabine significantlyll viability. The anti-cancer drug sensitivity in the Caov-3 (A), A2780CP
reated with the indicated concentrations of Cisplatin with or without
s assessed using the MTS assay as described under “Materials and
Figure 2 Gemcitabine enhances the Cisplatin-induced inhibition of cell invasion. Caov-3 (A), A2780CP (B) and A2780 (C) cells were treated
with or without 100 μM of Cisplatin for 24 hours in combination with 100 nM of Gemcitabine for 12 hours. The invasive potential of the cells was
examined using an invasion assay, as described under “Experimental Procedures”. Significant differences from the vehicle group are indicated by
asterisks. **, p < 0.01.
Figure 3 Gemcitabine attenuates Cisplatin-induced survival Akt signals and enhances apoptosis in Cisplatin-resistant cell lines. Caov-3
(A), A2780CP (B) and A2780 (C) cells were treated with or without 100 μM of Cisplatin for 24 hours in combination with 100 nM of Gemcitabine
for 12 hours. The cell lysates were subjected to SDS-PA GE, followed by a Western blot analysis with an anti-phospho-Akt (Ser473) antibody (top
parts of A, B and C) and an anti-Akt antibody (bottom parts of A, B and C). The PARP proenzyme (116 kD) is indicated in the top parts, and the
cleaved subunit (85 kD) is indicated in the bottom parts (D). The levels of Cisplatin-induced MMP9 phosphorylation are indicated in the top parts
of E, F and G, and the relative levels to the β-actin expression are indicated in the bottom parts of E, F and G. MMP-9 activity in Caov-3 cells was
measured with a gelatin-zymography. The Pro-MMP9 is indicated in the top parts, and the Active-MMP9 is indicated in the bottom parts (H). The
respective band densitometry analyses were performed using the Image J software program. The values represent the mean ± SE of at least three
independent experiments. Significant differences are indicated by asterisks.**p < 0.01, * p < 0.05.
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ylation, as shown in Figure 3A and 3B. Co-treatment
with Cisplatin and Gemcitabine resulted in a 78% de-
crease in comparison to the Western blotting band in-
tensities of phosphorylated Akt in the Caov-3 and
A2780CP cells treated with Cisplatin alone.
We examined whether Gemcitabine affects the Akt ac-
tivity induced by Cisplatin in the Caov-3 cells. PARP is a
substrate of caspase-3 that is also cleaved to produce the
85 kDa apoptotic fragment [23]. Co-treatment with Cis-
platin and Gemcitabine significantly induced the cleav-
age of PARP; however, Cisplatin did not induce cleavage
of PARP in the Caov-3 cells (Figure 3D). These results
suggest that Gemcitabine promotes apoptosis by sup-
pressing the Akt kinas activity induced by Cisplatin in
Caov-3 cells that are resistant to Cisplatin.
Effects of the inhibition of the MMP9 activity in the
Cisplatin-resistant cell lines induced by Gemcitabine
We examined the MMP9 activity following treatment
with Cisplatin or Gemcitabine individually and in com-
bination, as co-treatment with Cisplatin and Gemcita-
bine inhibited the invasion of both of these cell lines
through the Matrigel. We observed that both Cisplatin
and Gemcitabine had no effect on the levels of MMP9
activation in the Caov-3 cells compared with that ob-
served in the Caov-3 cells treated without these agents.
Gemcitabine had no effect on the levels of MMP9 acti-
vation. However, co-treatment with Cisplatin and Gem-
citabine resulted in a 78% decrease in comparison to the
Western blotting band intensities of phosphorylated
MMP9 in the Caov-3 cells treated with Cisplatin alone,
as shown in Figure 3E. We also examined the MMP-9
activity using a zymographic assay. We observed that
neither cisplatin nor gemcitabine had a significant effect
on the levels of MMP9 activation in the Caov-3 cells
compared with that observed in the Caov-3 cells treated
without these agents. However, co-treatment with cis-
platin and gemcitabine resulted in a 97% decrease in the
zymographic assay band intensities of active MMP9
compared to the Caov-3 cells treated with cisplatin
alone, as shown in Figure 3H.
Gemcitabine blocks the vascular endothelial growth
factor expression induced by Cisplatin
We examined the VEGF expression in the Caov-3 cells
treated with vehicle, Cisplatin alone, Gemcitabine alone
or the combination of Cisplatin and Gemcitabine using
an RT-PCR analysis (Figure 4). The combination of Cis-
platin and Gemcitabine significantly decreased the ex-
pression of the VEGF gene compared with that achieved
by Cisplatin alone. These results indicate that combin-
ation therapy consisting of Cisplatin and Gemcitabine
inhibits not only the Akt activity, but also the VEGFexpression induced by Cisplatin treatment (Additional
file 2: Figure S2).
Effects of Gemcitabine on the Cisplatin-induced inhibition
of intra-abdominal dissemination of ovarian cancer
Peritoneal dissemination is the primary route of progres-
sion in human ovarian cancer, and the amount of ascites
and disseminated tumor burden correlates with the pa-
tient prognosis in humans [24]. We therefore examined
the effects of treatment with Cisplatin and Gemcitabine
alone and in combination on the control of intra-
abdominal ovarian cancer dissemination, ascites formation
and tumor growth in order to assess whether combination
therapy increases the therapeutic efficacy of each agent.
Athymic nude mice were inoculated i.p. with Caov-3 cells,
as described in the Materials and Methods Section. The
appearance of the mice is shown in Figure 5A-I. Intra-
abdominal dissemination was clearly detected in the athy-
mic nude mice inoculated i.p. with Caov-3 cells followed
by treatment with PBS (Figure 5A-II and 5A-III). The
combination of Cisplatin and Gemcitabine further en-
hanced the inhibitory effects on the production of ascites
and intra-abdominal dissemination (Figure 5A-II, 5A-III).
After performing a histological examination (Figure 5B),
the abdominal tumors were found to be papillary adeno-
carcinomas, consistent with the characteristics of Caov-3
cells. The mean abdominal circumference six weeks after
the initiation of treatment in the mice treated with com-
bination therapy consisting of Cisplatin and Gemcitabine
was significantly lower than that observed in the mice
treated with PBS or Cisplatin alone (Figure 5C), suggest-
ing that the production of ascites was inhibited by treat-
ment with Gemcitabine. The disseminated tumor volume
six weeks after the initiation of treatment in the mice
treated with combination therapy consisting of Cisplatin
and Gemcitabine was also significantly lower than that ob-
served in the mice treated with PBS or Cisplatin alone
(Figure 5D, Additional file 3: Figure S3).
Gemcitabine inhibits the angiogenic activity induced by
Cisplatin and induces the apoptotic activity in the intra-
abdominal disseminated ovarian cancer model
We next examined whether Gemcitabine induces the
apoptotic activity and inhibits the proliferative and
angiogenetic activity in vivo. Figure 6A shows the apop-
totic activity measured using a TUNEL assay. The num-
ber of apoptotic cells was significantly increased upon
combined treatment with Cisplatin and Gemcitabine
compared to that observed in the mice treated with the
vehicle, Cisplatin alone or Gemcitabine alone. The intra-
tumoral microvessel density and Ki67 index significantly
decreased upon combined treatment with Cisplatin and
Gemcitabine compared to those observed in the mice
treated with the vehicle, Cisplatin alone or Gemcitabine
Figure 4 Gemcitabine significantly inhibits the Cisplatin-induced VEGF gene expression in Caov-3 cells. The cells were treated with or
without 100 μM of Cisplatin for 24 hours in the presence or absence of 100 nM of Gemcitabine for 12 hours. Total RNA was isolated and reverse
transcribed, and the resulting cDNA was used for PCR to detect the VEGF gene (upper panel). The level of β-actin was detected as an internal
control (lower panel).* p < 0.05.
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platin and Gemcitabine combination therapy signifi-
cantly induces apoptosis and inhibits the proliferative
and angiogenic activity.
Discussion
In this study, we demonstrated synergism between the
effects of Gemcitabine and Cisplatin in several ovarian
cancer cell lines. The most pronounced effects were ob-
served in the Cisplatin-resistant cell lines. The manage-
ment of platinum-resistant ovarian cancer remains
unsatisfactory. Resistance to Cisplatin is a multifactorial
phenomenon, the elements of which may be placed in
three general categories: (a) reduced intracellular accu-
mulation of Cisplatin, (b) elevated levels of glutathione
and metallothionein, and (c) increased tolerance or re-
pair of DNA damage [25-27]. Because Cisplatin acts by
forming intrastrand and interstrand DNA cross-links
and DNA protein cross-links, thus resulting in DNA
damage, overcoming these lesions with heightened re-
pair mechanisms is an important factor for Cisplatin re-
sistance [28]. We previously reported that the PI3K/Akt
cascade plays a role in Cisplatin resistance [12-14]. Ithas been demonstrated that Cisplatin resistance is pri-
marily due to the reduction of DNA damage and the
evasion of apoptosis, the latter of which includes the loss
of damage recognition and activation of the PI3K/Akt
pathway [29,30]. Although it is well known that Gemcita-
bine is one of the most active drugs in patients with
platinum-resistant ovarian carcinoma, the mechanisms
underlying these phenomena have not yet been character-
ized. In previous studies, Peters G.J., et al. showed that the
combination of Cisplatin and Gemcitabine produces syn-
ergistic effects in platinum-resistant ovarian cancer cells
[28]. Moufarij M.A., et al. and Ledermann J.A., et al. dem-
onstrated the inhibitory effects of Gemcitabine on the
repair of Cisplatin-induced intrastrand adduction and
interstand cross-linking in platinum-resistant ovarian can-
cer cells [31,32]. However, these authors did not indicate
either the mechanisms or the signal cascades underlying
the synergistic effects of such combination treatment with
Cisplatin and Gemcitabine in platinum-resistant ovarian
cancer cells. In this study, we found that combination
treatment with Cisplatin and Gemcitabine significantly in-
hibits the level of the Cisplatin-induced Akt activity in
Cisplatin-resistant cell lines (Caov-3 and A2780CP cells).
Figure 5 Gemcitabine enhances the cisplatin-induced inhibition of intra-abdominal dissemination. Athymic nude mice were inoculated
i.p. with Caov-3 cells. Two weeks after the inoculation of Caov-3 cells, as described in the Materials and Methods section, the athymic mice were
randomly assigned to one of four groups treated with different regimens for six weeks. (A) Physical appearance of representative mice. The
combination of Cisplatin and Gemcitabine reduced the production of ascites (I) and intra-abdominal dissemination (II and III). (B) Magnified views
of the intra-abdominal dissemination pattern in the vehicle mice and histological findings (×200 magnification) of hematoxylin and eosin staining
of parietal peritoneal dissemination in the athymic nude mice. (C) Relative ratios of the abdominal circumferences in each group. The
combination of Cisplatin and Gemcitabine significantly decreased the mean abdominal circumference six weeks after the initiation of treatment.
Significant differences are indicated by asterisks. **p < 0.01, *p < 0.05.
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by interfering with the antiapoptotic machinery and sig-
nificantly enhancing PARP cleavage. Moreover, we found
that combination treatment with Cisplatin and Gemcita-
bine significantly inhibits both the levels of invasive activ-
ity and the Cisplatin-induced MMP9 activity in Caov-3
and A2780CP cells; however, these effects are not achieved
with treatment with either Cisplatin or Gemcitabine alone.
We found that Cisplatin induced the VEGF expression
in the Cisplatin-resistant cell lines. Combined treatment
with Cisplatin and Gemcitabine significantly inhibits the
Cisplatin-induced VEGF expression in platinum-resistant
ovarian cancer cells, although no such effects are observed
after treatment with either Cisplatin or Gemcitabine
alone. Moreover, we found that combined treatment con-
sisting of Cisplatin and Gemcitabine significantly inhibits
intra-abdominal tumor cell dissemination and ascites
production compared to that observed following treat-
ment with Cisplatin or Gemcitabine alone. Whether
these phenomena are represented by other anticancer
agents is unclear. It has been reported that Topotecan, a
topoisomerase-1 inhibitor, inhibits the Akt and VEGF
cascade in platinum-resistant ovarian cancers [16].
However, 5-fluorouracil (5-FU), which exhibits similar
in vitro findings to the thymidylate synthase inhibitor,has no effect on the synergistic inhibition of cell viability
in Caov-3 cells after combined treatment with Cisplatin
and 5-FU, and does not inhibit the Cisplatin-induced Akt
activity in Caov-3 cells (Additional file 4: Figure S4A,
S4B). We found that Gemcitabine is a most effective mo-
lecular targeting agent with the ability to suppress the Akt
kinase activity, the ability to induce cellular apoptosis and
an anti-angiogenic activity in platinum-resistant ovarian
cancer cell lines.
In the current clinical trial, the response rate to treat-
ment with Gemcitabine and Cisplatin ranged from 16%
to 64% in the Cisplatin-resistant ovarian carcinomas
with measurable disease, although the frequency of
grade 3 and 4 neutrophil toxicity ranged from 20% to
81.5% and the platelet toxicity ranged from 36% to
96.5% [19,20,33-35]. It is said that one must take into
consideration that the use of less toxic and single agent
drugs may be worthwhile in a treatment process that
may span many years. However, previous clinical studies
have shown that Gemcitabine and Cisplatin can be used
to treat patients who have developed platinum-
resistance and failed to respond to other second-line
therapies over time, using a combination therapy that
may result in an appropriate response [20]. In the
present study, we were unable to show whether other
Figure 6 Analysis of apoptosis and angiogenesis in the tumors growing intra-abdominally in the athymic nude mice model.
Five-micron sections obtained from the liver, bowels and uterus of the athymic nude mice were fixed in formalin and embedded in paraffin then
prepared for the immunohistochemical analyses. The combination of Cisplatin and Gemcitabine significantly induced apoptosis (A), inhibited the
angiogenic activity (B) and depressed the MIB-1 index (C). Significant differences are indicated by asterisks. **p < 0.01, *p < 0.05.
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vated levels of glutathione and metallothionein, affect the
resistance of Cisplatin-resistant ovarian cancer. Such know-
ledge may be helpful for developing future strategies to
more effectively circumvent the multifactorial mechanisms
of platinum resistance. We believe that our data provide
scientific justification for both previous and future trials of
combination treatment with Gemcitabine and Cisplatin in
patients with platinum-resistant ovarian cancer.
In conclusion, we herein demonstrated that Gemci-
tabine inhibits the Akt kinase activity and angiogenetic
activity following treatment with Cisplatin in platinum-
resistant ovarian cancer cells. These results provide a
rationale for using Gemcitabine in clinical regimens
containing molecular targeting agents against platinum-
resistant ovarian cancers.Additional files
Additional file 1: Figure S1. Gemcitabine sensitivity in Caov-3 (A),
A2780CP (B) and A2780 (C) cells. The cells were treated with Gemcitabine
at various concentrations for 24 hours. The number of viable cells was
assessed using an MTS assay, as described in the Materials and Methods
section. **p < 0.01. , *p < 0.05.
Additional file 2: Figure S2. Effect of combination treatment with
Cisplatin and Gemcitabine on the VEGF mRNA expression in A2780CP (A)
and A2780 (B) cells. The cells were treated with various combinations of
100 nM of Gemcitabine and 200 μM of Cisplatin for six hours. Total RNA
was isolated and reverse transcribed, and the resulting cDNA was used inPCR for the semi-quantification of the VEGF mRNA expression relative to
that of β-actin. The values represent the mean ± S.E.M. of at least three
separate experiments. Significant differences are indicated by asterisks.
**p < 0.01.
Additional file 3: Figure S3. Effects of Cisplatin and Gemcitabine on
tumor growth in vivo. Athymic nude mice were inoculated i.p. with
A2780CP cells. Two week after inoculation, as described in the Materials
and Methods section, the athymic mice were inoculated i.p. with
A2780CP cells. (A) Physical appearance of representative mice. The
combination treatment with Cisplatin and Gemcitabine reduced tumor
production. (B) Magnified views of the tumor in the Vehicle mouse and
the histological findings (×200 magnification) of hematoxylin and eosin
staining. (C) Relative ratio of the abdominal circumference (I) and tumor
weight (II) in each group. The combination therapy with Cisplatin and
Gemcitabine significantly decreased the mean abdominal circumference
and tumor weight six weeks after the initiation of treatment. Significant
differences are indicated by asterisks. **p < 0.01, *p < 0.05.
Additional file 4: Figure S4. Effects of 5-FU on cell viability and Akt
phosphorylation in Caov-3. (A) The cells were treated with Cisplatin at
various concentrations with (□) or without (×) 100 nM of 5-FU for
24 hours. The number of viable cells was assessed using an MTS assay, as
described in the Materials and Methods section. (B) The cells were treated
with various combinations of 100 nM of Gemcitabine and 200 μM of
Cisplatin for 10 minutes. The cell lysates were subjected to Western
blotting for phosphor-Akt (upper panel) and Akt (lower panel), with the
density of the control bands arbitrarily set at 1.0. The values represent the
mean ± S.E.M. of at least three separate experiments. Significant
differences are indicated by asterisks. **p < 0.01.Abbreviations
PI3K-Akt: Phosphatidylinositol 3-kinase-Akt; RT-PCR: Reverse transcription
polymerase chain reaction; PARP: Poly (ADP-ribose) polymerase;
MMP9: Matrix metalloproteinase 9; VEGF: Vascular endothelial growth factor;
5-fluorouracil: 5-FU; MTS assay: 3-(4,5-dimethylthiazol-2-yl)-5-(3-
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